Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence
Open Access
- 1 January 2013
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (47) , 8895-901
Abstract
Chronic hepatitis B virus (HBV) infection is the key driving force of liver disease progression, resulting in the development of hepatic dysfunction, cirrhosis and hepatocellular carcinoma (HCC). The primary aim of therapy is to suppress or eliminate HBV replication to reduce the activity of hepatitis, thus reducing the risk of, or slowing the progression of, liver disease. Nucleos(t)ide analogues (Nucs) may result in rapid suppression of HBV replication with normalization of serum transaminases and restore liver function, thus increasing survival in patients with hepatic decompensation. Long-term Nuc therapy may result in histological improvement or reversal of advanced fibrosis and reduction in disease progression, including the development of HCC. The long-term benefits of a finite course of interferon (IFN)-α therapy also include a sustained and cumulative response, as well as hepatitis B surface antigen seroclearance and reduction in the development of cirrhosis and/or HCC. Pegylated IFN and newer Nucs may achieve better long-term outcomes because of improved efficacy and a low risk of drug resistance. However, treatment outcomes are still far from satisfactory. Understanding the effects of anti-HBV treatment against HCC incidence and recurrence after hepatectomy or liver transplantation is required for further improvement of outcome.Keywords
This publication has 54 references indexed in Scilit:
- Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA LevelsAnnals of Surgery, 2013
- Diverse roles of hepatitis B virus in liver cancerCurrent Opinion in Virology, 2012
- Involvement of hepatitis B virus X gene (HBx) integration in hepatocarcinogenesis via a recombination of HBx/Alu core sequence/subtelomeric DNAFEBS Letters, 2012
- Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative ResectionAnnals of Surgery, 2012
- Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2008
- A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular CarcinomaAnnals of Surgery, 2007
- Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis BHepatology, 2004
- New Era of Liver Transplantation for Hepatitis BAnnals of Surgery, 2002
- Long–Term Beneficial Effect of Interferon Therapy in Patients With Chronic Hepatitis B Virus InfectionHepatology, 1999
- The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic miceOncogene, 1997